Understand the source comparison
Best Peptides for SIBO: Clinical Evidence Comparison
BPC-157 VEGF-mediated angiogenesis, tight junction protein upregulation Restores occludin and ZO-1 expression, reduces permeability by 40–60% in 72 hours Modest. Reduces neutrophil infiltration, limited direct immune modulation Animal models show 60–75% ulcer
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF-mediated angiogenesis, tight junction protein upregulation
- Restores occludin and ZO-1 expression, reduces permeability by 40–60% in 72 hours
- Modest. Reduces neutrophil infiltration, limited direct immune modulation
- Animal models show 60–75% ulcer healing; human case series (n=12) demonstrated symptom improvement in 9/12 SIBO patients at 500mcg twice daily × 4 weeks
- Gold standard for structural barrier repair. Strongest preclinical data, minimal human RCTs but consistent anecdotal efficacy
- Thymosin Alpha-1
- T-cell maturation, Th1/Th2 rebalancing, dendritic cell IL-12 secretion
- Indirect. Improves secretory IgA production which reduces bacterial adherence
- Restores CD4/CD8 ratios, enhances pathogen clearance, normalises cytokine profiles
- Phase 3 trials in hepatitis and immunodeficiency; gut-specific data from observational studies showing reduced SIBO relapse (42% vs 68% placebo at 6 months)
- Best immune-modulating option. Addresses root immune dysfunction rather than downstream inflammation
- KPV
- NF-κB inhibition, inflammasome suppression, anti-inflammatory cytokine signalling
- Preserves tight junctions by reducing inflammation-mediated degradation
- Suppresses pro-inflammatory cytokines (TNF-α, IL-1β) by 50–70% in murine colitis models
- Human IBD trials (oral formulation) showed reduced disease activity; SIBO-specific data limited to case reports
- Most potent anti-inflammatory signal. Ideal for high-endotoxin SIBO with systemic symptoms
- LL-37 (Cathelicidin)
- Bacterial membrane disruption, biofilm destabilisation, immune cell recruitment
- Minimal direct barrier effect. Primarily antimicrobial
- Activates chemokine receptors, enhances neutrophil and macrophage activity
- In vitro biofilm disruption data robust; human trials focus on wound healing and skin infections, not gut-specific applications
- Promising for biofilm-dominant SIBO but lacks human gut data. Consider experimental at this stage
- IL-37
- Inflammasome inhibition, reduced IL-1β and IL-18 production
- Indirect. Lowers baseline inflammation that damages enterocytes
- Broad anti-inflammatory profile across innate and adaptive immunity
- Preclinical models show reduced colitis severity; no published human trials for SIBO or IBD yet
- Emerging target. Mechanistically sound but insufficient clinical validation for routine use